• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Molecular Testing Advances Improve Pediatric Disease Diagnosis and Outbreak Tracking

by
November 12, 2026
in Health
Reading Time: 6 mins read
0
Molecular Testing Advances Improve Pediatric Disease Diagnosis and Outbreak Tracking

Molecular Testing Advances Improve Pediatric Disease Diagnosis and Outbreak Tracking

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Advances in molecular diagnostics presented at the Association for Molecular Pathology 2026 Annual Meeting demonstrate how genetic testing and sequencing technologies can detect pediatric disorders earlier, refine cancer classifications, and track infectious disease outbreaks affecting newborns. The showcased investigations span neonatal screening evaluations, reanalysis of existing genomic datasets, novel tumor profiling methodologies, machine learning applications in leukemia subtyping, and pathogen surveillance in critical care settings. Together, these clinical and translational studies illustrate how molecular techniques are being adapted to address complex diagnostic challenges in pediatric medicine while managing constraints such as tissue availability and diagnostic turnaround times.

In adolescent medicine and newborn screening, researchers at Rady Children’s Institute for Genomic Medicine evaluated the potential of early whole-genome sequencing to uncover conditions years before symptoms manifest. In a retrospective review of genetic testing results from 177 adolescents between the ages of 13 and 19, investigators identified positive genetic findings in 64 patients, representing an overall diagnostic yield of 36.2 percent. Notably, eight of these positive findings satisfied the specific eligibility criteria for an existing newborn genomic screening program, indicating that systematic genomic testing at birth could have identified these actionable conditions years earlier in a subset of patients.

A related investigation led by researchers at the same institute addressed the diagnostic utility of phenotype-driven reanalysis of genomic data when pediatric patients develop new or evolving clinical signs. Analyzing clinical genome sequencing data from 21 children, the study identified new or additional genetic findings in five cases, representing 24 percent of the cohort. These findings emerged both in patients whose original tests were negative and in those who had already received an established genetic diagnosis. The newly detected variants included variants of uncertain significance that provided plausible explanations for progressive symptoms, with neurological and developmental alterations being particularly frequent among children with additional findings. Because reanalysis was triggered directly by observed clinical changes, the investigators noted that the study design could not directly compare this event-driven workflow with routine reanalysis conducted at fixed calendar intervals.

Addressing diagnostic precision in pediatric oncology, investigators at Children’s Hospital Los Angeles and the Keck School of Medicine of USC evaluated a whole-genome enzymatic methylation sequencing assay designed for central nervous system tumors. Molecular profiling of childhood brain tumors often necessitates multiple separate diagnostic assays that rapidly deplete scarce biopsy tissue. The evaluated single-workflow test integrates DNA methylation-based tumor classification with copy-number profiling using an optimal DNA input of 20 nanograms, while maintaining diagnostic utility with inputs as low as 2 nanograms when quality-control standards are satisfied.

Among 202 pediatric central nervous system tumors analyzed with the enzymatic methylation test, 195 specimens (96.5 percent) produced an interpretable, reportable methylation-family classification. Of those reportable classifications, 176 (90.3 percent) demonstrated complete concordance with the established integrated reference diagnosis. Furthermore, copy-number profiles generated by the assay were completely concordant with standard clinical chromosomal microarray results in 24 of 29 evaluated cases, with the remaining five cases exhibiting directional concordance, highlighting the platform’s capacity to conserve scarce tumor samples while delivering comprehensive molecular profiles.

In another pediatric cancer study, researchers from the Instituto Nacional de Medicina Genómica in Mexico developed an ensemble machine learning classifier to improve the accessibility of molecular subtyping for B-cell acute lymphoblastic leukemia in resource-limited clinical environments. Accurate molecular subtyping is vital for pediatric leukemia risk stratification and therapy selection, yet conventional comprehensive profiling tools frequently remain cost-prohibitive. Utilizing targeted RNA sequencing, the machine learning model achieved an overall classification accuracy of 82.3 percent across 12 distinct molecular subtypes in a cohort of 170 pediatric patients, though classification performance varied across specific disease subtypes.

Germline genetic factors in pediatric brain malignancies were examined in a study conducted at Nationwide Children’s Hospital analyzing genomic data from 587 children with medulloblastoma enrolled in the Molecular Cancer Initiative. The frequency of germline predisposition variants varied widely across tumor subtypes, reaching 41.8 percent among children diagnosed with the sonic hedgehog molecular subgroup of medulloblastoma, underscoring the clinical importance of germline testing for family counseling and tailored management.

Beyond oncology and rare genetic disorders, molecular diagnostics proved essential for infectious disease surveillance during a deadly mpox outbreak in Sindh, Pakistan, characterized by reverse vertical transmission and community dissemination. Researchers confirmed 33 mpox infections from 305 suspected clinical cases, with 21 of the confirmed infections occurring in pediatric patients. The outbreak resulted in the deaths of nine infants younger than two months of age.

The highlighted pediatric studies form part of the broader scientific program scheduled for the Association for Molecular Pathology 2026 Annual Meeting and Expo, taking place from November 10 through November 14 at the Seattle Convention Center. Founded in 1995, the Association for Molecular Pathology serves as a global molecular diagnostic professional society representing more than 3,100 members internationally. The organization’s multidisciplinary membership includes clinical laboratory directors, pathologists, basic and translational scientists, technologists, and trainees who work across academic medical centers, community hospitals, government facilities, and industry settings. Within the professional society, members operate across key disciplines of molecular diagnostics encompassing inherited conditions, oncology, infectious diseases, and bioinformatics. Through standing working groups, specialized committees, and its governing Board of Directors, the professional society works to establish structure and guidance for diagnostic practice, influence health policy and regulatory frameworks at national and international levels, advance technological innovation, and protect patient access to appropriate diagnostic testing.

Presentations dedicated to inherited conditions and adolescent genomic testing begin with research delivered by Jennifer Schleit, Ph.D., from Rady Children’s Institute for Genomic Medicine, scheduled as an oral presentation on Thursday, November 12 at 2:30 p.m., followed by a poster presentation on Saturday, November 14 at 9:15 a.m. Her study, detailed under abstract G017, focuses on rapid and ultra-rapid whole-genome sequencing applications in an adolescent cohort. Rapid genomic sequencing has become an established clinical tool for identifying underlying conditions in critically ill neonates who require urgent diagnostic resolution. The evaluation in 177 adolescents aged 13 to 19 examined whether testing performed at birth could detect inherited genetic disorders that otherwise remain unrecognized across childhood. By identifying positive diagnostic results in 64 patients, the investigation demonstrated that roughly one-third of the adolescent cohort carried diagnosable genomic variants.

Further genomic reanalysis findings from Rady Children’s Institute for Genomic Medicine are scheduled for Saturday, November 14 at 9:15 a.m. under abstract G027, presented by Jing Zhang, M.D., Ph.D. This investigation focused on phenotype-driven reanalysis of clinical genome sequencing data to examine whether emergence of new clinical manifestations justifies revisiting previously generated sequencing profiles. In pediatric medicine, clinical presentations frequently evolve as children age, introducing neurological and developmental changes that were not apparent during initial baseline diagnostic assessments. By demonstrating that reanalysis yielded actionable diagnostic findings in 24 percent of the 21 children evaluated, the study showed equivalent utility between patients with prior negative evaluations and those with existing diagnoses. However, because each reanalysis was triggered directly by observed changes in patient symptoms rather than systematic protocol, the research could not assess or contrast the effectiveness of symptom-prompted evaluations against scheduled reanalysis conducted at fixed intervals.

Diagnostic advancements in pediatric central nervous system oncology are scheduled for presentation on Saturday, November 14 at 1:45 p.m. under abstract ST015 by Jianling Ji, M.D., representing Children’s Hospital Los Angeles and the Keck School of Medicine of USC. Conventional molecular assessment of pediatric brain malignancies routinely requires deploying multiple distinct analytical platforms to establish methylation classifications and copy-number changes, a diagnostic sequence that can quickly exhaust minimal tissue samples obtained from surgical biopsies. The whole-genome enzymatic methylation sequencing test evaluated in the study was developed to unify methylation-based classification and chromosomal copy-number profiling within a single diagnostic run. Operating with a standard optimal DNA input of 20 nanograms, the platform also sustained reliable testing down to 2 nanograms of input material whenever strict quality-control criteria were satisfied, thereby providing a practical option for conserving minimal tissue while obtaining definitive diagnostic classifications.

Additional presentations focusing on pediatric hematologic and solid tumor malignancies include research by Joaquín García-Solorio, Ph.D., from the Instituto Nacional de Medicina Genómica in Mexico, presenting abstract H011 on Saturday, November 14 at 9:15 a.m. His team developed an ensemble machine learning classifier for B-cell acute lymphoblastic leukemia molecular subtyping utilizing targeted RNA sequencing, offering an accessible diagnostic workflow designed for healthcare systems operating in resource-limited environments. In pediatric brain tumor genetics, Swetha Ramadesikan, Ph.D., of Nationwide Children’s Hospital presents abstract G022 on Thursday, November 12 at 3:30 p.m. and Friday, November 13 at 9:15 a.m., examining germline predisposition in 587 children with medulloblastoma, where inherited risk variants were identified in 16.2 percent overall and reached 41.8 percent in sonic hedgehog subgroup cases. Finally, infectious disease surveillance research presented under abstract ID045 by Saeed Khan, Ph.D., from Dow University of Health Sciences, scheduled for Friday, November 13 at 12:55 p.m., details the genomic epidemiology of the 2026 neonatal healthcare-associated mpox outbreak in Sindh, Pakistan, where transmission modeling and whole-genome sequencing helped trace reverse vertical and community pathways following 33 confirmed infections and nine neonatal deaths.

Subject of Research: Pediatric molecular diagnostics and genomic testing advances presented at the AMP 2026 Annual Meeting

Article Title: AMP 2026 Annual Meeting to highlight advances in molecular testing for pediatric diseases

Article References: AMP 2026 Annual Meeting to highlight advances in molecular testing for pediatric diseases. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: molecular diagnostics, pediatric genetics, whole-genome sequencing, AMP 2026, newborn genomic screening, phenotype-driven reanalysis, central nervous system tumors, enzymatic methylation sequencing, medulloblastoma, cancer predisposition variants, B-cell acute lymphoblastic leukemia, machine learning classification, targeted RNA sequencing, mpox outbreak, genomic surveillance, neonatal infections

News Source: Harold Sullivan. (November 12, 2026). Molecular Testing Advances Improve Pediatric Disease Diagnosis and Outbreak Tracking. Scienmag.

Tags: AMP 2026B-cell acute lymphoblastic leukemiacancer predisposition variantscentral nervous system tumorsenzymatic methylation sequencingGenomic surveillanceMachine learning classificationmedulloblastomaMolecular diagnosticsmpox outbreakNeonatal infectionsnewborn genomic screeningpediatric geneticsphenotype-driven reanalysistargeted RNA sequencingwhole-genome sequencing
Share12Tweet7Share2ShareShareShare1

Related Posts

Pesticide Handlers in Tanzanian Agriculture Show Significant Acetylcholinesterase Enzyme Suppression

Pesticide Handlers in Tanzanian Agriculture Show Significant Acetylcholinesterase Enzyme Suppression

November 18, 2026
Rare Unilateral Neuroretinitis Linked to Dengue Infection in Returning Traveller

Rare Unilateral Neuroretinitis Linked to Dengue Infection in Returning Traveller

November 18, 2026

Coated Intramedullary Nails Yield Low Infection Rates in High-Risk Long-Bone Fractures

November 18, 2026

Older Age and Lower BMI Associated With Lower Teicoplanin Trough Concentrations

November 18, 2026

POPULAR NEWS

  • Electroacupuncture Mobilizes Unique CD34-Positive Stem-Like Cells in Healthy Dogs

    Electroacupuncture Mobilizes Unique CD34-Positive Stem-Like Cells in Healthy Dogs

    29 shares
    Share 12 Tweet 7
  • Specialists Outline Cervical Cancer Screening Principles for Resource-Limited Settings

    29 shares
    Share 12 Tweet 7
  • Modified Halpern Proximal Algorithm Solves Multi-Structured Problems in Curved Hadamard Spaces

    29 shares
    Share 12 Tweet 7
  • Machine Learning Outperforms Pharmacokinetic Models Predicting Initial Vancomycin Concentrations in Septic Patients

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Pesticide Handlers in Tanzanian Agriculture Show Significant Acetylcholinesterase Enzyme Suppression

Rare Unilateral Neuroretinitis Linked to Dengue Infection in Returning Traveller

Coated Intramedullary Nails Yield Low Infection Rates in High-Risk Long-Bone Fractures

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.